Japan panel OKs world's first human trial with iPS cells
This article was originally published in Scrip
Japan has recommended approval of the world's first clinical trial for a regenerative therapy based on induced pluripotent stem (iPS) cells, for the treatment of the most common form of age-related macular degeneration (AMD).
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.